Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A real-life setting study evaluating the clinical utility of liquid biopsy for the early diagnosis of EGFR mutant advanced lung cancer

Next Previous
Trial Profile

A real-life setting study evaluating the clinical utility of liquid biopsy for the early diagnosis of EGFR mutant advanced lung cancer

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 12 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Osimertinib (Primary)
  • Indications Adenocarcinoma; Lung cancer
  • Focus Therapeutic Use
  • Acronyms CLEAR

Most Recent Events

  • 24 Oct 2023 Results (n=312; Between November 2019 and January 2023) assessing plasma and tissue EGFR testing and the clinical impact on the management of suspected lung cancer patients, presented at the 48th European Society for Medical Oncology Congress.
  • 24 Nov 2021 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top